Stockreport

Matinas BioPharma Provides Comment on Impact of Vascepa® Patent Litigation on MAT9001 and Update on COVID-19 Pandemic’s Effect on Business Operations and Clinical Programs

Matinas Biopharma Holdings, Inc.  (MTNB) 
NASDAQ:AMEX Investor Relations: ir.matinasbiopharma.com
PDF BEDMINSTER, N.J., March 31, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today commented on [Read more]